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ABSTRACT  
G protein receptor kinases (GRKs) and β-arrestins are key regulators of μ-opioid receptor (MOP) 
signaling and trafficking. We have previously shown that high-efficacy opioids such as DAMGO 
stimulate a GRK2/3-mediated multisite phosphorylation of conserved C-tail Ser and Thr residues, 
which facilitate internalization of the receptor. In contrast, morphine-induced phosphorylation is 
limited to Ser375 and it is not sufficient to drive substantial receptor internalization. Here, we 
report how specific multisite phosphorylation controls the dynamics of GRK and β-arrestin 
interactions with MOP and show how such phosphorylation mediates receptor desensitization. 
We show that the kinetics of GRK2/3 recruitment to a DAMGO-activated MOP are faster than the 
kinetics of β-arrestin recruitment. β-arrestin recruitment requires GRK2 activity and MOP 
phosphorylation, but surprisingly, GRK recruitment is also dependent on the integrity of the 
phosphorylation sites in the C-terminus. Translocation of both regulatory proteins and their stable 
interaction with MOP are dependent on phosphorylation of four Ser and Thr residues within the 
370TREHPSTANT379 motif of the C-tail. Our results also suggest that other residues outside this 
motif participate in the initial and transient recruitment of GRK and β-arrestins. Finally, using 
complementary patch clamp approaches, we show that high efficacy agonist desensitization of 
MOP has two components; a sustained component, which requires GRK2-mediated 
phosphorylation and a potential soluble factor, and a rapid component likely mediated by GRK2 
but independent of receptor phosphorylation. Elucidating these complex receptor-effector 
interactions represents an important step towards a mechanistic understanding of MOP 





Opioids such as morphine are still the mainstay analgesics for the treatment of severe pain. 
However, the development of tolerance, addiction and respiratory depression severely limits their 
utility (1). These unwanted effects of opioids are key contributors to opioid-induced overdose 
deaths, which have drastically increased in the last decade (2).  
The µ-opioid receptor (MOP) is the G protein-coupled receptor (GPCR) targeted by morphine and 
most opioid analgesics (3). Since the initial observation that morphine elicited less tolerance and 
decreased side effects in mice lacking β-arrestin2 (4, 5), substantial efforts have focused on the 
development of opioid ligands that preferentially activate G protein-mediated signals over β-
arrestin recruitment. These efforts have resulted in the discovery of several molecules with an 
improved side effect profile and increased therapeutic window (6-8). However, the cellular 
mechanisms whereby opioids mediate analgesia vs other side effects are far from clear. MOP 
desensitization is considered to be the initial step for the development of tolerance. Such 
desensitization entails phosphorylation of the receptor, recruitment of regulatory proteins such as 
β-arrestins and receptor internalization (1). Together, these regulatory processes result in a 
reduction of opioid response or sensitivity. 
The ligand-dependent and hierarchical nature of MOP phosphorylation and its role in MOP 
desensitization and internalization has been previously established. Quantitative mass 
spectrometry and phosphorylation site-specific antibodies have identified two clusters of MOP 
residues, 354TSST357 and 370TREHPSTANT379 within its C-terminal region, that undergo opioid-
induced phosphorylation (9-11). Agonist-mediated phosphorylation of MOP is initiated at Ser375, 
but it is the ability of such agonists to induce higher order phosphorylation on flanking residues 
that dictates their propensity to internalize MOP. Different opioids produce different 
phosphorylation patterns; multisite phosphorylation in the C-terminal region of MOP occurs 
robustly for agonists that induce internalization with less phosphorylation of fewer sites for those 
that do not (9-11).  
Rapid desensitization of MOP coupling to membrane effectors such as voltage-gated calcium 
channels (VGCCs) and inwardly rectifying K channels (GIRKs; Kir3.X) also precedes internalization, 
but its relationship to phosphorylation events and β-arrestin recruitment remains unclear (1, 12). 
We have previously shown that C-terminal phosphorylation of MOP is necessary for some forms of 
desensitization, but that this effect is also ligand dependent (13). Mutation of all Ser and Thr 
residues within the C-terminal tail of MOP completely abolished [Met5]-enkephalin (ME)-, but not 
morphine-, induced desensitization. In vivo, introduction of a S375A mutation in transgenic mice 
diminished the development of tolerance to high-efficacy opioid agonists such as DAMGO or 
etonitazene, while tolerance to chronic morphine appeared unaffected (14). Compound 101 
(Cmpd101), a small molecule inhibitor that prevents G protein receptor kinase (GRK) 2/3 
activation (15), only partially blocked ME-, DAMGO- and morphine-induced MOR desensitization 
of GIRKs in rat and mouse locus coeruleus neurons (16), suggesting GRK2/3-independent 
mechanisms of MOP desensitization. 
It is now clear that multisite phosphorylation of MOP induced by high intrinsic efficacy agonists 
such as DAMGO or ME requires GRK2/3 (11), and that activation of MOP by these ligands results in 
β-arrestin recruitment to the receptor (17-19). Overexpression of GRK2 also facilitates morphine-
induced β-arrestin recruitment and MOP internalization (20), supporting a key role of this kinase in 
MOP regulation. However, it is still unknown what dictates GRK-MOP interactions. Moreover, 
Raveh et al. (21) have proposed that GRKs may act to desensitize GIRK channels via a mechanism 
that is independent of their kinase activity through competition for the βγ subunits of the G 
protein that activate these channels. 
It is thus clear that GRKs and arrestins are critical regulatory proteins for which interaction with 
MOP prior to internalization has major implications for opioid signaling. However, the molecular 
determinants that control these interactions are still elusive. How phosphorylation regulates these 
interactions and what relevance this has for MOP desensitization are questions that remain to be 
addressed. 
 
In the present study, we report a systematic assessment of how specific multisite phosphorylation 
controls the dynamics of GRK and β-arrestin interactions with MOP and show how such 
phosphorylation mediates receptor desensitization. Using Bioluminescence and Förster Resonance 
Energy Transfer (BRET and FRET) as well as β-galactosidase (β-Gal) complementation technology, 
we show that the kinetics of GRK2/3 recruitment to a DAMGO-activated MOP are faster than the 
kinetics of β-arrestin recruitment. β-arrestin recruitment requires GRK2 activity and MOP 
phosphorylation, but surprisingly, GRK recruitment is also dependent on the integrity of the 
phosphorylation sites in the C-terminus of MOP. While the 370TREHPSTANT379 motif is required for 
effective recruitment of GRKs and β-arrestins, the 354TSST357 region participates in the long-term 
stability of such interactions. Interestingly, both GRKs and β-arrestins show residual recruitment to 
a mutant receptor with all C-terminal phosphosites mutated. Finally, using complementary patch 
clamp approaches, we unravel a fast desensitization event that is independent of MOP 
phosphorylation as well as a sustained desensitization component, which requires GRK2-mediated 
phosphorylation of the 370TREHPSTANT379 motif and a potential soluble factor. Elucidating these 
complex receptor-effector interactions represents an important step towards a mechanistic 





Agonist-dependent recruitment of β-arrestins to wild-type MOP 
We have recently developed complementary approaches that allow for the systematic 
investigation of the dynamics and mechanisms of β-arrestin recruitment to MOP. FRET and BRET 
allow the real-time assessment of the recruitment of a fluorescently tagged β-arrestin (CFP or YFP, 
respectively) to a C-terminally tagged MOP (YFP or RLuc8, respectively). In addition, we have also 
developed a β-galactosidase (β-Gal) complementation approach to measure steady-state 
interactions between β-arrestin and MOP. Thus, while FRET and BRET provide information about 
the dynamics of β-arrestin recruitment at early time points, the β-Gal complementation assay 
provides further insight into the stability of these interactions (Figure 1A).  
The high intrinsic efficacy agonist DAMGO and the low intrinsic efficacy opiate morphine (both at 
1µM) increased the BRET signal between MOP-RLuc8 and β-arrestin2-YFP to reach a maximum 
within 1 min, although the signal obtained with morphine was smaller than that obtained with 
DAMGO (Figure 1B). Importantly, this signal was blocked by addition of the antagonist naloxone 
(30µM), showing specificity and reversibility of the response (Figure 1B). FRET measurements 
between MOP-YFP and β-arrestin2-CFP showed similar results (Figure 1C) (22). Activation of MOP 
with saturating concentrations of DAMGO (10µM) promoted β-arrestin2 recruitment to the 
receptor that reached its maximal signal within 1 min and was reversed after agonist removal. 
Saturating concentrations of morphine (30µM) also induced β-arrestin2-CFP recruitment to MOP-
YFP, although with a lower FRET signal (Figure 1C). 
We then constructed concentration-response curves for β-arrestin1 and β-arrestin2 recruitment 
using BRET (10 min incubation) or β-Gal complementation assays (1 h incubation) (Figure 1D-G). 
DAMGO induced a concentration-dependent recruitment of β-arrestin1 and β-arrestin2 in both 
assays with similar potencies (Table 1). In contrast, morphine did not significantly induce β-
arrestin1 recruitment, and caused only a partial recruitment of β-arrestin2 with similar potency as 
DAMGO (Table 1). These results are in agreement with previous findings that show a 
compromised ability of morphine to recruit β-arrestins in the absence of GRK overexpression (18, 
20).  
Recruitment of β-arrestins to phosphorylation-deficient MOP mutants 
To map putative phosphate acceptor sites controling MOP phosphorylation, we generated 
phosphorylation-deficient MOP mutants and directly assessed the correlation between 
phosphorylation and recruitment of regulatory proteins. Receptor phosphorylation at candidate 
sites was evaluated using phosphosite-specific antibodies (Figure 2A). Mutations of Ser and Thr 
(S/T) residues to alanine (A) in different regions of wild-type (WT) MOP generated the following 
phosphorylation-deficient MOP mutants: TSST-4A (mutations in the 354TSST357 cluster), S375A 
(mutation of Ser375), STANT-3A (mutations in the 375STANT379 cluster), TREHPSTANT-4A (mutations 
in the 370TREHPSTANT379 motif) and 11S/T-A (mutation of all 11 potential C-terminal S/T 
phosphorylation sites) (Figure 2A). 
Consistent with earlier observations, no constitutive phosphorylation of Ser356/Thr357, Thr370, 
Ser375, Thr376 or Thr379 was observed. Agonist stimulation with morphine resulted in 
phosphorylation of Ser375 and only induced weak phosphorylation of the Thr370, Thr376 and Thr379 
residues. In contrast, DAMGO resulted in robust MOP phosphorylation at all the sites contained 
within 370TREHPSTANT379 domain (Figure 2B) (10, 11). Equivalent receptor loading was confirmed 
by detecting a distinct non-phosphorylated epitope in the cytoplasmic tail.  
Expanding from previous studies, we generated a phosphosite-specific antiserum against Ser356 
and Thr357 of the 354TSST357 motif of the MOP C-terminal tail (pS356/pT357). DAMGO stimulation 
induced very weak phosphorylation of these residues, which was abolished in the TSST-4A mutant. 
Morphine did not promote any phosphorylation of these residues (Figure 2B). In addition, 
mutation of the 354TSST357 motif in the TSST-4A mutant produced a modest decrease in the 
phosphorylation at other S/T sites by both ligands. This excludes both Ser356/Thr357 as prominent 
initial sites for agonist-induced MOP phosphorylation but highlights that the integrity of the 
354TSST357 cluster might be important for regulatory events that depend on robust phosphorylation 
within the 370TREHPSTANT379 domain. 
Point mutation of Ser375 (S375A mutant) within the 375STANT379 motif, prevented detectable 
phosphorylation at Ser356/Thr357, Thr376 and Thr379, and also significantly reduced phosphorylation 
at Thr370 (Figure 2B). This confirms Ser375 as the initial residue for agonist-specific hierarchical MOP 
phosphorylation as previously reported (10, 11). As expected, detection of phosphorylated MOP 
by any of the phospho-specific antibodies was blocked by mutation of the 370TREHPSTANT379 motif 
or mutation of all S/T residues in the cytoplasmic tail (11S/T-A mutant) (Figure 2B). 
To directly assess the relationship between receptor phosphorylation and the recruitment of β-
arrestin1/2, we generated phosphorylation-deficient MOP mutants (Figure 2A) suitable for BRET, 
FRET and β-Gal complementation assay. Correct expression and function of these mutants was 
evaluated by anti-FLAG ELISA and inhibition of forskolin-induced cAMP of FLAG-tagged MOP 
constructs without C-terminal tags (Supplemental Figure 1, Supplemental Table 1).  
Mutation of the 354TSST357 cluster (TSST-4A) had no effect on DAMGO-induced β-arrestin1 or β-
arrestin2 recruitment when measured using BRET (Figure 3A, B and C, Tables 2 and 3). However, 
when the interaction between β-arrestins and MOP was detected using β-Gal complementation, 
deletion of this cluster led to a significant decrease of absolute β-arrestin1 and β-arrestin2 
recruitment (Emax), while the potency of DAMGO remained unchanged (Figure 3B and C, Table 2 
and 3). β-Gal complementation requires the two fragments to be in the correct relative 
orientation to form a functional enzyme, which has been suggested to occur upon “stable” 
interactions (30-90 min). In contrast, for FRET and BRET to occur, the relative orientation between 
the receptor and β-arrestin is under fewer constraints. Thus, these data suggest that while the 
initial recruitment of β-arrestins to the receptor may not be affected by mutation of the 354TSST357 
motif, the stability of this interaction is affected upon mutation of this motif to alanine. Thus, 
phosphorylation of the 354TSST357 region, although not directly involved in β-arrestin recruitment, 
may participate in the stability of the β-arrestin/MOP complex.  
Mutation of the 375STANT379 cluster (STANT-3A) or 370TREHPSTANT379, significantly affected 
DAMGO-induced β-arrestin1 and β-arrestin2 recruitment to MOP in both BRET and β-Gal 
complementation assays (Figure 3A-C), respectively. Although DAMGO’s potency was unaffected 
in this mutant, there was a ~50% reduction of the maximal effect of this ligand (Table 2 and 3). 
These results suggest that the 375STANT379 motif plus Thr370 are a key region for receptor-arrestin 
interactions, most likely participating in the initial recruitment of β-arrestin to the activated 
receptor. Within this region lies Ser375, which drives the hierarchical phosphorylation of MOP. 
Interestingly, single mutation of S375A affected the dynamics of β-arrestin2 recruitment. While 
the BRET response to DAMGO within the first 5 minutes after stimulation was similar to the WT 
receptor, the signal rapidly decayed to levels similar to those measured for the STANT-3A mutant 
(Figure 3A) and although the potency of DAMGO at this mutant was similar to that of the WT 
receptor, its maximal effect was reduced by 30% (Table 3). As expected, in the β-Gal 
complementation assay the recruitment induced by DAMGO at the MOP S375A was significantly 
affected (Figure 3B and C, Table 3). In addition, FRET experiments between MOP S375A-YFP and β-
arrestin2-CFP also showed significant effects of this mutation on β-arrestin2 recruitment (Figure 
3D). Together these results not only support the observations that phosphorylation of Ser375 
serves as an initial residue for multisite phosphorylation but also suggest that this site is key to 
prolonging the interaction between MOP and β-arrestins. Finally, we assessed β-arrestin2 
recruitment to a mutant receptor where all the phosphorylation sites of the C-tail have been 
mutated to alanine (11S/T-A). As expected, at this mutant DAMGO-induced β-arrestin1/2 
recruitment was significantly compromised in all the three assays (Figure 3, Table 2 and 3). 
Of note, we observed that although the DAMGO-induced BRET signal was dramatically reduced in 
the STANT-3A and 11S/T-A mutants, it was not completely abolished (i.e it still increased from 
basal levels upon addition of the agonist). Interestingly, addition of the antagonist naloxone 
(30µM) was able to completely reverse the BRET signal to basal levels (Supplemental Figure 2). A 
similar effect could also be observed in the FRET assay after agonist removal (Figure 3D), although 
recruitment of β-arrestin2 was not detected for the two phosphorylation-deficient mutants in the 
β-Gal complementation assay. These data suggest that even in the absence of phosphorylation 
sites in the C-tail of the MOP, β-arrestins can be transiently recruited to the receptor upon agonist 
stimulation.  
We also investigated the effects of the above mutations on morphine-induced β-arrestin2 
recruitment. As observed in the WT receptor, the response induced by morphine was significantly 
weaker than that induced by DAMGO (Figure 3A, Table 3). However, the effect of all mutations on 
morphine’s effects mirrored those observed for the high efficacy agonist DAMGO.    
As β-arrestin recruitment precedes MOP internalization (1), we assessed the ability of DAMGO to 
promote endocytosis of MOP phospho-deficient mutants using BRET, cell-surface ELISA and 
confocal imaging. DAMGO stimulation of WT receptor (but not morphine stimulation) induced an 
increase of the BRET signal between MOP-RLuc8 and an early endosome resident protein (Rab5a-
Venus) (Figure 4A). This was also observed in cell-surface ELISA assay, which quantifies agonist-
induced reduction of cell surface receptor (Figure 4B). Confocal imaging of the HA-tagged MOP 
and phospho-deficient mutants (Supplemental Figure 1C) also confirmed these data. Mutations of 
354TSST357motif had a weak effect on DAMGO-induced MOP internalization (Figure 4A, B), however 
mutations S375A, STANT-3A, TREHPSTANT-4A or 11S/T-A severely impaired receptor endocytosis. 
These results are in agreement with the β-arrestin recruitment data, and support the requirement 
of a strong and sustained MOP-β-arrestin interaction to drive receptor internalization. 
Role of GRKs in β-arrestin recruitment  
Agonist-induced phosphorylation of MOP is mediated by GRKs. In particular, GRK2 and GRK3 are 
mainly involved in MOP phosphorylation upon stimulation with high-efficacy agonists, such as 
DAMGO (11). We thus investigated the influence of overexpression, knockdown and 
pharmacological inhibition of GRK2/3 on β-arrestin recruitment using BRET and β-Gal 
complementation approaches.  
As expected, overexpression of GRK2/3 resulted in increased efficacy and potency of DAMGO- and 
morphine-induced β-arrestin1 (Supplemental Figure 3A) and β-arrestin2 recruitment in both 
assays (Figure 5A-D and Table 4). In addition, and extending previous studies that showed that 
GRK2 overexpression increases Ser375 phosphorylation by morphine, we show that GRK2/3 
overexpression facilitates morphine-induced multiphosphorylation at Thr370 and Thr379 contained 
within the 370TREHPSTANT379 motif (Figure 5E). Depletion of endogenous GRK2 or GRK3 alone by 
siRNA or by overexpression of a catalytically inactive GRK2 (GRK2 K220R, GRK2-DN) had a small 
effect in reducing the efficacy of DAMGO and morphine to recruit β-arrestin2 (Figure 5A and F, 
Table 4). Inhibition by a specific inhibitor of GRK2/3, Compound 101 (Cmpd101) (15), resulted in 
inhibition of DAMGO-induced β-arrestin2 recruitment (Figure 5G). Finally, the effect of GRK2 
expression levels and activity on MOP internalization was evaluated using BRET between MOP-
RLuc8 and Rab5a-Venus. In agreement with the β-arrestin recruitment data and with previous 
reports, MOP internalization in response to both DAMGO and morphine was enhanced by GRK2 
overexpression and abolished by incubation with Cmpd101 (Supplemental Figure 3B). Together 
these results illustrate the key role of GRK2/3 in the recruitment of β-arrestins and receptor 
endocytosis induced by opioid agonists.  
GRK recruitment to activated wild type and phosphorylation-deficient MOP mutants 
To understand the dynamics and mechanisms of GRK recruitment to MOP, we developed FRET, 
BRET and β-Gal complementation approaches with the same donor-acceptor pairs used in the β-
arrestin assays described above. Real time measurements of FRET between MOP-YFP and GRK2-
mTurquoise or BRET between MOP-RLuc8 and GRK2-Venus showed that GRK2 recruitment to the 
activated receptor occurs faster than β-arrestin translocation (half time [t1/2] = 2.3 s for GRK2 FRET 
and t1/2 = 20s for GRK2 BRET vs t1/2 = 42s for β-arrestin2 FRET and t1/2 = 66s for β-arrestin2 BRET; 
Supplemental Figure 4) and reversed to basal upon agonist removal or addition of 30 µM naloxone 
(Figure 6A and B). Concentration-response curves constructed using BRET or β-Gal 
complementation assays estimated a potency of 0.6 µM for DAMGO and 0.43 µM for morphine 
(Figure 6C and D, Table 5). Similar results were obtained for GRK3 in the β-Gal complementation 
assay (Supplemental Figure 4). Cmpd101 completely prevented GRK2 recruitment to activated 
MOP (Figure 6E) suggesting that an active GRK2 is required for its interaction with MOP. 
We next sought to understand the role of phosphorylation within MOP C-tail on GRK2 
translocation. We obtained similar results to the β-arrestin recruitment data described above. 
Namely, mutation of the 354TSST357 motif (TSST-4A) did not affect early BRET measurements 
(Figure 7A and B, Table 6) while it had a robust effect on GRK2 recruitment measured by β-Gal 
complementation (Figure 7C, Table 6). These results again suggest a role of this region in the 
stability of interactions between the receptor and regulatory proteins. Mutations S375A, STANT-
3A and 11S/T-A all had a significant effect in reducing GRK2 recruitment in both assays (Figure 7A-
C). Similar results were obtained for GRK3 in the β-Gal complementation assay (Supplemental 
Figure 4).  
FRET experiments using the S375A and 11S/T-A mutants and GRK2-mTurquoise showed agonist-
induced recruitment of GRK2 to phosphorylation-deficient mutants that was reversible after 
agonist washout (Figure 7D). Again, it is interesting to note that, as with β-arrestin2 recruitment, 
although the BRET signal was dramatically reduced in the STANT-3A and 11ST/-A mutants, it was 
not completely abolished (i.e. it still increased fro basal levels upon addition of the ligand) and 
only addition of the antagonist naloxone (30µM) was able to completely return the BRET signal to 
basal levels (Supplemental Figure 4). These data support the notion that even in the absence of 
phosphorylation sites at the C-tail of the MOP, GRKs and β-arrestins can be transiently recruited to 
the receptor upon agonist stimulation. 
Desensitization of phosphorylation-deficient MOP mutants. 
Phosphorylation sites in the vicinity of 354TSST357 and 375STANT379 have been shown to play 
important roles in MOP desensitization. Using conventional whole cell mode of patch clamp 
recording, Birdsong et al. (2015) reported that STANT-3A mutation and, more substantially, 
STANT-3A plus TSST-4A impaired desensitization by ME in neurons (23). By contrast, using 
perforated patch clamp recording to limit disruption of the cytoplasmic milieu, we previously 
reported that mutation of 6 S/T residues, including STANT, abolished ME-induced internalization 
but did not inhibit desensitization and that impairment of ME-induced desensitization required 
mutation of all 11 S/T residues in the C-tail (13). We therefore compared desensitization of the 
STANT-3A and TSST-4A mutants using both whole cell and perforated patch clamp recording. As 
previously reported (13) an initial rapid component of GIRK desensitization (with a time constant 
of approximately 2-4 s) was observed upon application of ME (10µM) for both TSST-4A and 
STANT-3A mutants that was not significantly different from WT MOP (Supplemental Figure 5). This 
rapid component was not observed using a concentration of ME below 100nM and was less 
prominent during application of morphine than ME (10µM; Supplemental Figure 5). This most 
likely reflects GIRK regulation by GRK2 that is recruited to the receptor-channel complex by ME 
but less effectively by morphine, as suggested previously (21). However, it should be noted that 
the potency of ME to induce this rapid desensitization component could not be resolved as the on-
rate of ME activated GGIRK overlaps substantially at low concentrations with the on-rate of the 
declining component (Supplemental Figure 5A). 
Using perforated patch clamp, both STANT-3A and TSST-4A mutants showed acute desensitization 
upon exposure to supramaximal concentrations of both ME and morphine (10µM), similar to WT 
MOP (Figure 8A and D). An acute decline of GIRK conductance was observed during the 5 min 
exposure to both ME and morphine for both the mutants and WT. As previously reported, the 
decline in peak GIRK conductance is an insensitive measure of receptor desensitization because of 
the large receptor reserve present in these cells (13, 24). Desensitization of the response to a 
submaximal concentration of ME (10nM) was highly significant for TSST-4A, STANT-3A and WT  
MOP (P < 0.0001 in each case; One sample t-test). Of note, and as previously reported  (13), a 
smaller component of heterologous desensitization of responses to somatostatin acting on 
somatostatin receptors natively expressed in AtT20 cells was observed in all mutants 
(Supplemental Figure 5E). By contrast, desensitization by ME was significantly reduced under 
whole cell patch clamp recording in the STANT-3A mutant (77±8 % in whole cell patch vs 19±3% in 
perforated patch) but was maintained in TSST-4A and WT MOP (18±3% for TSST-4A and 22±5% for 
WT MOP, Figure 8B and E and Supplemental Figure 6). These results suggest that diffusion out of 
the cell of cytoplasmic desensitization mediators occurs during whole cell but not perforated 
patch clamp recording conditions.  
We and others have previously reported that inhibition of protein kinase C (PKC) impairs MOP 
desensitization (13, 25). Moreover, we previously reported that PKCα caused restricted receptor 
mobility upon activation by morphine but not DAMGO (26). To assess the role of PKC, cells were 
pre-incubated with the PKC inhibitor, Calphostin C, and were exposed to the inhibitor throughout 
recordings. Calphostin C (30nM) did not affect desensitization by ME in WT or TSST-4A MOP but 
significantly reduced ME induced desensitization of STANT-3A (Figure 8C and F). These data 
suggest that ME-induced desensitization by soluble mediators of the STANT-3A mutant is sensitive 
to PKC inhibition, in a similar manner as previously observed for morphine at the WT MOP (13). 
DISCUSSION 
This study identifies the role of multisite phosphorylation of MOP in promoting receptor 
interactions with GRKs and β-arrestins and mediating rapid receptor desensitization. We have 
systematically mutated the 11 Ser and Thr residues present in the C-tail of MOP. The use of 
complementary approaches to measure protein-protein interactions permits the assessment of 
the dynamics of complex formation and provides key information about the roles that different C-
terminal motifs play in such dynamic interactions. 
The 354TSST357 cluster in the proximal region of the C-tail of MOP does not participate in receptor 
internalization (Figure 4) (9). However, Birdsong et al. identified the TSST region as a major 
mediator of the generation of the high-affinity state of the receptor upon high efficacy agonist 
stimulation, suggesting that phosphorylation of this motif can have an allosteric effect on ligand 
binding (23). Our data shows that although mutation of the 354TSST357motif (TSST-4A) did not 
abolish phosphorylation, it did induce a detectable decrease in multisite phosphorylation induced 
by DAMGO (Figure 2). Interestingly, for this mutant, recruitment of GRK2/3 and β-arrestins within 
the first 30 min remained unaffected (Figures 3 and 7), whereas no detectable recruitment 
occurred after 1 h incubation, as observed using the βGal complementation approach (Figures 3 
and 7). Moreover, desensitization of TSST-4A MOP was indistinguishable from WT (Figure 8). 
Together, these results suggest that the TSST region, by allosterically modulating ligand binding, 
participates in the stability of the interaction of MOP with regulatory proteins but has no impact 
on MOP desensitization and internalization.  
Our data support previous findings suggesting that Ser375 serves as an initial residue that drives 
hierarchical multisite phosphorylation of MOP (11, 27). As we have previously described, single 
mutation of this residue severely compromised phosphorylation of other Ser and Thr residues 
(Figure 2B). Moreover, phosphorylation of Ser375 had a significant impact on the dynamics of 
recruitment of GRK2 and β-arrestin (Figures 3 and 7). S375A MOP was still able to recruit GRK2 
and β-arrestin at early time points (5 min), however, the interaction of these proteins with the 
mutant receptor were very transient. We detected a steady decrease in the β-arrestin recruitment 
BRET signal after 5 min, and no detectable recruitment was observed after 1 h incubation (Figures 
3 and 7). The use of complementary assays that rely on different stability constraints (β-Gal 
complementation vs FRET and BRET) has allowed for the detection of these different dynamics 
dictated by receptor phosphorylation. The compromised internalization of S375A also suggests 
that robust phosphorylation and stable interactions with GRK2 and β-arrestins are required to 
drive MOP endocytosis.  Ser375 is the first residue of the 375STANT379 motif. This region has 
previously been reported to play a key role in receptor internalization (9), although conflicting 
results have been reported regarding the ability of this mutant to desensitize (13, 23). In the 
present study we reconcile the differences observed with regards to the desensitization of this 
mutant (Figure 8). Our data clearly suggest that the 375STANT379 region is crucial for regulating 
MOP desensitization. High efficacy agonists like DAMGO and ME regulate MOP desensitization by 
a GRK2/β-arrestin-mediated mechanism upon phosphorylating crucial sites within this region. 
Moreover, the observation that the compromised desensitization of the STANT-3A mutant is only 
detectable when using whole cell patch clamp further suggests the requirement of a soluble 
(cytosolic) factor as a mediator of this desensitization. In agreement with this, we show that 
GRK2/3 and β-arrestin recruitment, as well as receptor internalization at STANT-3A MOP were 
severely compromised (Figures 3, 4 and 7). The key role of the 375STANT379 region in the regulation 
of MOP is also illustrated by the results obtained upon mutation of all Ser and Thr residues within 
the C-tail of MOP (11ST/A) (Figures 3, 4 and 7). 
Due to its limited ability to induce multisite phosphorylation of MOP (Figure 2B), morphine 
induced very weak recruitment of β-arrestins (Figures 1 and 5). Overexpression of GRK2/3 
facilitated phosphorylation of Thr370 and Thr379 (in addition to Ser375) by morphine, which resulted 
in both increased β-arrestin recruitment and MOP internalization (Figure 5 and Supplemental 
Figure 3). These results highlight that the cellular effect of a particular ligand (in this case 
morphine) is highly dependent on the cellular context, and that differences in expression levels of 
signaling and regulatory proteins will influence the downstream events of receptor activation in a 
particular cell type. For example, different expression levels of GRK2 may explain why morphine 
internalizes MOP in striatal neurons (28) but not in other neurons (29), although this remains to be 
confirmed. 
An important finding of the current study is that even when all Ser and Thr residues of the C-tail of 
MOP were mutated to Ala, we were able to detect GRK2 and β-arrestin recruitment using BRET 
and FRET approaches but not when using the β-Gal complementation assay. Importantly, these 
signals were abolished by addition of the antagonist naloxone or by agonist washout 
(Supplemental Figures 2 and 4). These results suggest that both GRK2 and β-arrestins can be 
transiently recruited to the activated MOP independently of receptor phosphorylation. Indeed, 
phosphorylation-independent recruitment of β-arrestins has been reported for several GPCRs (30, 
31). Moreover, this recruitment of GRK2 is likely to mediate the rapid component of GIRK 
desensitization (21), which still occurred in the STANT-3A mutant (Supplemental Figure 5). 
It is well established that GRKs play a key role in GPCR regulation, that they phosphorylate 
activated receptors, uncoupling them from G proteins and facilitating interactions with β-arrestins 
to promote alternative signaling and/or receptor endocytosis. Indeed our results show that GRK2 
activity is required for efficient arrestin recruitment and MOP internalization (Figure 5 and 
Supplemental Figure 3). An unexpected result from our studies was that the interaction between 
GRK2 and the activated MOP also seemed to be dependent on the integrity of the 
phosphorylation sites (Figure 7). Cmpd101 prevented recruitment of GRK2 to the activated MOP, 
consequently compromising β-arrestin recruitment and receptor internalization. Binding of 
Cmpd101 to GRK2 induces small conformational changes that stabilize GRK2 in a non-active, non-
catalytic conformation (15). Thus, our results suggest that the unblocked conformation of GRK2/3 
is required for the recruitment and interaction of this kinase with MOP. 
Although the molecular mechanisms underlying the development of morphine-induced tolerance 
remain controversial, it is generally accepted that MOP desensitization of VGCC and GIRK channels 
is an important step. As mentioned above, our results suggest that MOP desensitization by high 
efficacy ligands has two components; a sustained component, which requires GRK2-mediated 
phosphorylation and a potential soluble factor, and a rapid component independent of receptor 
phosphorylation (Figure 8 and Supplemental Figure 5). This desensitization component, 
independent of kinase activity, highlights the potential dual role of GRKs, acting as 
scaffolding/sequestering proteins in addition to their kinase activity, as earlier suggested by Raveh 
et al. (21). In addition to GRKs, PKC has also been suggested to participate in the development of 
tolerance to morphine (25) , although the molecular basis of this remains unclear. Our patch 
clamp studies suggest that in the STANT-3A MOP mutant, PKC becomes important in mediating 
ME desensitization (Figure 5). Whether PKC phosphorylates Ser363 and/or Thr370 as previously 
suggested (32, 33) or whether PKC is the soluble factor mediating sustained desensitization, 
remains to be investigated. 
In summary our results demonstrate the complex role of MOP phosphorylation in receptor 
desensitization and in the recruitment of regulatory and scaffolding proteins. These receptor-
effector interactions are likely to participate in the control of physiological opioid effects such as 
tolerance and dependence. 
  
MATERIALS AND METHODS 
Reagents 
Morphine HCl was from GlaxoSmithKline or Merck Pharma. The rabbit polyclonal phosphosite-
specific antibodies anti-pS356/pT357 {4879}, anti-pT370 {3196}, anti-pS375 {2493}, anti-pT376 
{3723} and anti-pT379 {3686} were generated and extensively characterized previously (10, 11, 
13). The phosphorylation-independent rabbit monoclonal anti-MOP antibody {UMB-3} was 
obtained from Abcam-Epitomics (34). Secondary antibodies (raised in donkey) conjugated to 
Alexa-Fluor 488, 568 or 647 were from Jackson ImmunoResearch. Coelenterazine h was from 
NanoLight. Compound 101 was from HelloBio. DAMGO, ME, Calphostin C, amphotericin B and M2-
anti-FLAG were from SigmaAldrich.  
Plasmids 
For BRET experiments, β-arrestin1-YFP and β-arrestin2-YFP were provided by M. Caron (Duke 
University, NC), GRK2-Venus was from D. Jensen and Rab5a-Venus has been previously described 
(35). GRK2-WT and GRK2-DN (dominant negative – GRK2-K220R) were from M. Smit (Vrije 
Universiteit, Amsterdam). The phosphorylation deficient FLAG-MOP mutants and FLAG-MOP-
RLuc8 were purchased from GeneArt. For FRET experiments, GRK2-mTurquoise and GRK2-YFP 
have been previously described (36). β-arrestin2-mTurquoise was constructed by replacing the 
CFP coding sequence in β-arrestin2-CFP (37) with mTurquoise (38). For β-galactosidase 
complementation experiments, we adapted the plasmids according to PathHunterÒ (DiscoverX 
Patent: WO 2010042921 A1, US 20100120063 A1). The plasmids were generated via artificial gene 
synthesis by Eurofins Genomics and cloned into pcDNA3.1. Briefly, the coding sequence for an 
amino-terminal HA-tag was added to the wild-type MOP and the S/T-mutant sequences, whereas 
the C-terminal end was fused with a Gly-rich linker (GGGGSGGGGS) and a short β-Gal fragment (1-
44 amino acids). All acceptor plasmids, GRKs and β-arrestins had the larger β-galactosidase 
synthetic sequence fragment (45-1043 amino acids) fused to their C-terminal end. 
Small Interfering RNA Silencing of Gene Expression 
Double stranded siRNA duplexes with 3’-dTdT overhangs were obtained from Qiagen for GRK2 (5’-
AAGAAAUUCAUUGAGAGCGAU-3’), GRK3 (5’-AAGCAAGCUGUAGAACACGUA-3’) and a non-
silencing RNA duplex (5’- GCUUAGGAGCAUUAGUAAA-3’). HEK293 cells were transfected with 150 
nM siRNA for single transfection or with 100 nM of each siRNA for double transfection using 
HiPerFect (Qiagen). Silencing was quantified after 3 days by performing a GRK β-galactosidase 
complementation assay. All experiments showed that the siRNA reduced the target protein levels 
by ≥80%. 
Cell Culture 
Human embryonic kidney 293 (HEK293) were maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 5% v/v fetal bovine serum (FBS) at 37°C in a humidified atmosphere 
of 95% air and 5% CO2. Transient transfections for BRET experiments were performed using linear 
polyethylenemine (PEI) with a molecular weight of 25kDa (Polysciences) in a DNA:PEI ratio of 1:6 
as previously described (39). For FRET experiments, transient transfections were performed in 6 
cm dishes with Effectene (Qiagen) as previously described (36). For transient and stable 
transfections in β-galactosidase complementation experiments, TurboFect® DNA (Thermo Fisher 
Scientific) was used. Stably transfected cells were grown in medium supplemented with 400 
µg/mL G418 and/or 100 µg/mL Hygromycin B. To increase the total number of HEK293 cells stably 
expressing MOP or phosphorylation-deficient mutant receptors, we used fluorescence-activated 
cell sorting (FACS). Trypsinized cells were washed with PBS and transferred into opti-MEM 
containing an A488-labeled anti-HA antibody at a dilution of 1:1000 (SigmaAldrich). After 30 min 
preincubation at room temperature, cells were centrifuged and the cell pellet was resuspended in 
FACS buffer (2 mM EDTA, 0.5% w/v BSA in PBS). FACS was executed using a BD FACSAria III cell 
sorter. Approximately 1% of the positive cell population was sorted at an average purity of 85%. 
Sorted cells were then recultivated. To ensure similar expression levels of wild-type and mutant 
receptors, stable cells were characterized using Western blot analysis, surface ELISA assay and 
immunocytochemistry.  
Patch clamp experiments were performed in AtT20 cells, which endogenously express GIRK 
(KirX.3) channels. Wild type MOP, 354TSST357/A, 375STANT379/A were all cloned in pcDNA3.0 
plasmids with FLAG-tag and were expressed stably in AtT20 cells as previously described (13). For 
patch clamp experiments AtT20 cells were seeded on 35 mm polystyrene culture dishes (Beckton, 
Dickinson Biosciences) in DMEM containing 4.5 g/L glucose, penicillin-streptomycin (100µL/mL), 
G418 (50mg/mL) and 10% FBS (50mg/mL). Cell cultures were maintained in a humidified 5% CO2 
atmosphere at 37oC. Cells were ready for recording after 24 h. 
Bioluminescence Resonance Energy Transfer (BRET) 
HEK293 cells were transiently transfected in a 10 cm dish with 1 µg of donor (RLuc8-tagged MOP 
wild type or phosphorylation deficient mutant) and 4 µg of acceptor (β-arrestin1-YFP, β-arrestin2-
YFP, GRK2-Venus or Rab5a-Venus). For cAMP experiments cells were transiently transfected with 
the CAMYEL BRET biosensor (2.5 µg of FLAG-MOP and 2.5 µg of CAMYEL biosensor per dish). For 
GRK2 expression experiments, cells were transfected with an additional 2 µg of GRK2-WT, GRK2-
DN or pcDNA3 as a control. After 24 h, cells were re-plated into poly-D-lysine-coated white 
opaque 96-well plates (CulturPlate, PerkinElmer) and allowed to adhere overnight. BRET 
experiments were performed 48 h post-transfection. Cells were washed with Hank's Balanced Salt 
Solution (HBSS) and equilibrated in HBSS for 30 min at 37°C prior to the experiment. 
Coelenterazine h was added to a final concentration of 5 µM 10 min before dual 
fluorescence/luminescence measurement in a LUMIstar Omega plate reader (BMG LabTech). The 
BRET signal was calculated as the ratio of light emitted at 530 nm by YFP or Venus over the light 
emitted at 430 nm by Renilla luciferase 8 (RLuc8). For concentration-response curves, cells were 
stimulated with DAMGO (10-10M – 10-4M) or morphine (10-10M – 10-4M) for 10 min before BRET 
measurements. For short kinetic experiments (β-arrestin and GRK2 recruitment), the baseline 
BRET ratio was measured for 5 cycles, then either vehicle (0.01% v/v DMSO), DAMGO or morphine 
(both 1 µM) were added to the cells, and the BRET signal was measured for 30 minutes. For longer 
kinetic experiments (Rab5a), cells were stimulated with vehicle (0.01% v/v DMSO), DAMGO or 
morphine (both 1 µM) at different time points as stated over an interval of 100 min. 
Förster Resonance Energy Transfer (FRET) 
To measure the interaction between MOP and β-arrestins, HEK293T cells were transfected with 
0.8 µg MOP-YFP (or mutants), 0.4 µg human GRK2 and 0.8 µg β-Arrestin2-mTurquoise. To measure 
the interaction between MOP and GRK2, HEK293T cells were transfected with 0.5 µg MOP-YFP (or 
mutants), 0.5 µg rat Gɑi1, 0.5 µg human Gβ1, 0.4 µg murine Gγ2 and 0.5 µg GRK2-mTurquoise. On 
the next day, cells were seeded on round 25 mm poly-lysine-coated coverslips, and 48 h post-
transfection, FRET was measured as previously described  (36)except that a light-emitting diode 
(LED) excitation system (pE-2; CoolLED) was used for all experiments. FRET traces were not 
corrected for bleaching effects. 
β-Galactosidase Complementation  
HEK293 cells stably expressing MOP or mutant MOP constructs C-terminally fused with a β-
galactosidase enzyme fragment (β-Gal1-44), and stably or transiently expressing β-arrestins or GRKs 
fused to an N-terminal deletion mutant of β-galactosidase (β-Gal45-1043) were used (DiscoverX 
Patent: WO 2010042921 A1, US 20100120063 A1). β-arrestin or GRK recruitment results in 
complementation of the two β-galactosidase fragments that generate an active enzyme. Thus, 
levels of active enzyme are a direct result of MOP activation and are quantitated using 
chemiluminescent β-Gal-Juice-plus® detection reagents (PJK GmbH) containing the β-galactoside 
substrate. The assay was performed as follows: cells were plated into poly-L-lysine-coated 48-well 
plates at a density of 125,000 cells/well in medium supplemented with 400 µg/mL G418 and 
incubated overnight. After 48 h, test compounds were prepared at each concentration in DMEM 
and added to the cells. Following a 1 h incubation at 37°C, cell lysis reagent (1 M NaH2PO4 · H2O; 1 
M Na2HPO4 · 2 H2O, 0,1% v/v TritonX, pH 7.4) was added to each well. Luminescence was 
measured 1h post detection reagent addition (β-Gal Juice-plus®) using a FlexStation III (Molecular 
Devices, 500 ms integration time).  
Western Blot  
Cells were seeded onto poly-L-lysine-coated 60 mm dishes and grown to 80 % confluence. After 
treatment with agonist, cells were lysed in detergent buffer (50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 5 mM EDTA, 10 mM NaF, 10 mM disodium pyrophosphate, 1% v/v Nonidet P-40, 0.5% 
w/vsodium deoxycholate, 0.1% w/v SDS) in the presence of protease and phosphatase inhibitors 
(Complete mini- and PhosSTOP, Roche Diagnostics). Glycosylated proteins were partially enriched 
using wheat-germ lectin agarose beads as described (40, 41). Proteins were eluted from the beads 
using SDS-sample buffer for 20 min at 42 °C. Samples were split, resolved on 8% SDS-
polyacrylamide gels, and after electroblotting membranes were incubated with either anti-
pS356/pT357 {4879}, anti-pT370 {3196}, anti-pS375 {2493}, anti-pT376 {3723} or antipT379 {3686} 
antibodies followed by detection using an enhanced chemiluminescence detection system 
(Thermo Fisher Scientific). Blots were stripped and incubated again using the phosphorylation-
independent anti-MOP antibody {UMB-3} (34) to ensure equal loading of the gels. 
Enzyme-Linked Immunosorbent Assay (ELISA) 
HEK293 cells were transfected with 5 µg of DNA (pcDNA3 as a control, FLAG-MOP wild type or 
phosphorylation deficient mutants, in 10 cm dishes), after 24 h, re-plated into poly-D-lysine coated 
48-well plate and allowed to adhere overnight. After 48 h, cells were fixed with 3.7% v/v 
paraformaldehyde in Tris-buffered saline (TBS) for 30 min. For total expression, cells were 
permeabilized by 30 min incubation with 0.5% v/v NP-40 in TBS. Cells were then incubated in 
blocking buffer (1% w/v skim milk powder in 0.1M NaHCO3) for 4 h at room temperature and 
incubated with mouse M2-anti-FLAG antibody (1:2000, overnight at 4°C). After washing 3 times 
with TBS, cells were incubated with anti-mouse horseradish peroxidase (HRP)-conjugated antibody 
(1:2000) for 2 h at room temperature. Cells were washed and stained using the SIGMAFAST OPD 
substrate (SigmaAldrich). Absorbance at 490 nm was measured using an EnVision Multilabel 
Reader (PerkinElmer). Data were normalized to intact HEK293 cells transfected with MOP-WT. To 
measure MOP internalization, HEK293 cells stably expressing the HA-tagged MOP WT, MOP TSST-
4A, MOP S375A, MOP TREHPSTANT-4A or MOP 11S/T-A were preincubated with anti-HA antibody 
and stimulated with 10µM DAMGO for 30 min. Receptor sequestration, quantified as the 
percentage of residual cell surface receptors in agonist-treated cells, was measured by ELISA as 
described above.  
Confocal Imaging and Quantitative Analysis of MOP Internalization 
Stably transfected cells were grown on poly-L-lysine-coated coverslips overnight. Cells were then 
incubated with primary antibody (rabbit anti-HA) in serum-free medium for 2 h at 4°C. After 
agonist exposure, cells were fixed with 4% paraformaldehyde and 0.2% picric acid in phosphate 
buffer (pH 6.9) for 30 min at room temperature and washed several times with PBS. Specimens 
were permeabilized and then incubated with an Alexa488-conjugated goat anti-rabbit antibody 
(Santa Cruz Biotechnology). Specimens were mounted and examined using a Zeiss LSM510 META 
laser scanning confocal microscope. For quantitative internalization assays, cells were seeded onto 
24-well plates. On the next day, cells were preincubated with anti-HA antibody for 2 h at 4°C. Cells 
were then exposed to agonist at 37°C, fixed and developed with peroxidase-conjugated secondary 
antibody as described  (42, 43).  
Electrophysiology 
Patch clamp recordings were performed as previously described (13).  Pipettes were pulled from 
borosilicate glass (AM Systems) yielding input resistances between 3.5-4.5 MΩ. For perforated 
patch clamp recording, pipettes were filled with internal solution containing 135 mM potassium 
gluconate, 3 mM MgCl2, 10 mM HEPES (adjusted to pH 7.4 with KOH). The recording electrodes 
were first front filled with this internal solution and then backfilled with the same solution 
containing 200 µg/mL amphotericin B (in 0.8% DMSO). For whole cell recording, internal solution 
contained 135 mM Kgluconate, 8 mM NaCl , 8 mM HEPES, 0.5 mM EGTA, 3 mM MgATP, 0.5 mM 
Na2GTP (pH 7.3). Cells were initially superfused with external bath solution containing 140 mM 
NaCl, 3 mM KCl, 1.8 mM CaCl2, 1.2 mM MgCl2, 10 mM HEPES, and 10 mM glucose (pH 7.4). For 
measuring IGIRK, the KCl concentration in the bath was increased to 20 mM (substituted for NaCl) 
before the start of the measurements and was maintained throughout the experiments as 
previously described in Yousuf et al. (2015). Liquid junction potential was calculated to be +16 mV 
and was adjusted before the start of each recording. Currents were recorded at 37°C in a fully 
enclosed, temperature-controlled recording chamber using an Axopatch 200B amplifier and 
pCLAMP 9.2 software, and digitized using Digidata 1320 (Axon Instruments, Molecular Devices). 
Currents were sampled at 100 Hz, low pass filtered at 50 Hz and recorded on hard disk for later 
analyses. IGIRK was recorded using a 200 ms voltage step to -120 mV from a holding potential of -60 
mV delivered every 2 s. Drugs were perfused directly onto cells using a ValveLink 8.2 pressurized 
pinch valve perfusion system (AutoMate Scientific). In all recorded cells, solution exchange 
reached steady state within 200 ms (usually within 100 ms), which was confirmed by examination 
of the current produced at – 60 mV by switching from low (3 mM) to high (20 mM) K+ solution. 
All data points are plotted as chord GIRK conductance (GGIRK, nS) using the following calculation: 
[IGIRK (-60 mV) - IGIRK (-120 mV)] pA / 60 mV. The extent of MOP desensitization as a percentage 
was calculated using the following formula: (Post GME / Pre GME)*100, where, “Pre” and “Post GME” 
are the GGIRK increase induced by a submaximal probe concentration of ME (10nM; see 
Supplemental Figure 6), averaged for 4-5 points during the peak response (coloured points in 
figures), immediately before vs 1 min after termination of exposure to a supramaximal 
concentration of agonist (ME 10 μM or morphine 10 μM). Desensitization for different MOP 
mutants was analysed using a two-factor ANOVA followed by appropriate post-hoc tests as 
indicated. 
Statistics 
Data are presented as the mean ± SEM of n≥3 independent experiments. Differences were 
assessed with GraphPad Prism using one-way or two-way ANOVA followed by Bonferroni adjusted 
post-hoc tests for multiple comparisons. 
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Figure 1. Agonist-dependent recruitment of β-arrestin1 and 2 to wild-type MOP. (A) Schematic 
representation of the approaches used in this study: BRET, FRET and β-galactosidase 
complementation. (B) HEK293 cells expressing MOP-RLuc8 and β-arrestin2-YFP (BRET) were 
stimulated with 1 µM DAMGO or morphine for 20 min prior to addition of 30 µM naloxone (n=4). 
(C) HEK293 cells expressing MOP-YFP and β-arrestin2-CFP (FRET) were stimulated with 10µM 
DAMGO or 30µM morphine for 1 min prior to agonist washout (n=6). (D, E) HEK293 cells 
expressing MOP-RLuc8 and β-arrestin1/2-YFP (BRET) were stimulated for 10 min with increasing 
concentrations of DAMGO or morphine (n=6). (F, G) HEK293 cells expressing MOP-β-Gal1-44 and 
β-arrestin1/2-β-Gal45-1043 (β-Gal complementation) were stimulated with increasing 
concentrations of DAMGO or morphine for 1 h (n=4-6). Raw BRET/FRET ratio of vehicle-treated 
cells was subtracted and raw bioluminescence data from β-gal were normalized to vehicle-treated 
cells. Data points represent mean±SEM of the indicated number of experiments. 
Figure 2. C-tail phosphorylation of MOP. (A) Schematic representation of the C-tail domain of 
mouse MOP with potential phosphate acceptor sites depicted in grey and phosphosite-specific 
antibodies against pS/pT residues depicted in black (pS356/pT357, pT370, pS375, pT376 and 
pT379). The epitope recognized by the phospho-independent antibody UMB-3 is underlined. (B) C-
tail sequences of wild-type MOP (WT) and phosphorylation-deficient MOP mutants are also 
illustrated. Serine (S) and threonine (T) residues depicted in black were mutated to alanine (A) 
depicted in grey as shown in each of the mutants. (C) Characterization of phosphosite-specific 
antibodies using Western blot analysis. HEK293 cells stably expressing the HA-tagged MOP WT, 
MOP TSST-4A, MOP S375A, MOP TREHPSTANT-4A or MOP 11S/T-A, were stimulated with 10µM 
DAMGO or morphine for 30 min at 37°C. Cells were lysed and immunoblotted with anti-
pS356/pT357, anti-pT370, anti-pS375, anti-pT376 or anti-pT379 antibodies. Blots were stripped 
and reprobed with the phosphorylation-independent anti-MOP antibody UMB-3 or with anti-HA 
antibody to confirm equal loading. 
Figure 3. Recruitment of β-arrestin1 and 2 to phosphorylation-deficient MOP mutants. (A, B) (A) 
HEK293 cells were transiently transfected with MOP-RLuc8 WT or phosphorylation-deficient 
mutants and β-arrestin1/2-YFP (BRET) and stimulated for 30min with 1µM DAMGO or morphine 
(n=3-5). Raw BRET ratio of vehicle-treated cells was subtracted and data represent mean±SEM. 
Area under the curve (AUC) of BRET signal is shown as a percentage of the maximal response to 
DAMGO in the WT receptor and represents means±SEM. All responses are significant against 
vehicle; ^ denotes significance vs WT (p<0.01) two-way ANOVA with Dunnett's multiple 
comparison test; * denotes significance of DAMGO vs morphine (p<0.01) two-way ANOVA with 
Sidak's multiple comparison test. (B) HEK293 cells expressing MOP-RLuc8 WT or phosphorylation-
deficient mutants and β-arrestin2-YFP (BRET) or MOP-β-Gal1-44 WT or phosphorylation-deficient 
mutants and β-arrestin2-β-Gal45-1043 (β-Gal complementation) were stimulated with increasing 
concentrations of DAMGO or morphine for 10 min or 1 h, respectively. Data were normalized to 
vehicle-treated cells and represent mean±SEM (n=3-6). (C) HEK293 cells expressing MOP-RLuc8 
WT or phosphorylation-deficient mutants and β-arrestin1-YFP (BRET) or MOP-β-Gal1-44 WT or 
phosphorylation-deficient mutants and β-arrestin1-β-Gal45-1043 (β-Gal complementation) were 
stimulated with increasing concentrations of DAMGO or morphine for 10 min or 1 h, respectively. 
Data were normalized to vehicle-treated cells and represent mean±SEM (n=3-6). (D) HEK293 cells 
expressing MOP-YFP phosphorylation-deficient mutants and β-arrestin2-CFP (FRET) were 
stimulated with 10µM DAMGO or 30µM morphine for 1min prior to agonist washout (left panel 
n=14 for WT and n=15 for S375A; right panel n=17 for WT and 11S/T-A). n, number of experiments  
Figure 4. Internalization of phosphorylation-deficient MOP mutants. (A) Internalization BRET 
assay in HEK293 cells transiently transfected with MOP-RLuc8 WT or phosphorylation-deficient 
mutants and the early endosome marker Rab5a-Venus and stimulated with 1μM DAMGO. BRET 
ratio of vehicle-treated cells was subtracted. Data points represent mean±SEM (n=3-4). (B) 
HEK293 cells stably expressing the HA-tagged MOP WT, MOP TSST-4A, MOP S375A, MOP 
TREHPSTANT-4A or MOP 11S/T-A were preincubated with anti-HA antibody and stimulated with 
10µM DAMGO for 30 min. Receptor sequestration, quantified as the percentage of residual cell 
surface receptors on agonist-treated cells, was measured by ELISA (n=3). n, number of 
experiments 
Figure 5. Role of GRKs in β-arrestin recruitment. (A, B) HEK293 cells expressing MOP-RLuc8 and β-
arrestin2-YFP (BRET) and pcDNA3 (mock), GRK2-WT or GRK2-DN were stimulated for 10min with 
increasing concentrations of DAMGO or morphine and the BRET signal measured after stimulation 
(n=3). (C, D) HEK293 cells expressing MOP-β-Gal1-44 and β-arrestin1/2-β-Gal45-1043 (β-Gal 
complementation) and mock (pcDNA3), GRK2 or GRK3 for overexpression were stimulated with 
increasing concentrations of DAMGO or morphine for 1 h (n=3-6). For BRET, the ratio of vehicle-
treated cells was subtracted and for β-Gal, the data were normalized to vehicle-treated cells. Data 
points represent mean±SEM. (E) HEK293 cells expressing MOP alone (control) or in combination 
with pcDNA3 (mock), GRK2, GRK3 or both were stimulated with 10µM morphine for 30 min at 
37°C, lysed and immunoblotted with anti-pT370, anti-pS375, or anti-pT379 antibodies. Blots were 
stripped and reprobed with the phosphorylation-independent anti-HA antibody to confirm equal 
loading. (F) HEK293 cells expressing MOP-β-Gal1-44 and β-arrestin1/2-β-Gal45-1043 (β-Gal 
complementation) were co-transfected with scrambled (SCR), GRK2 or GRK3 siRNA and stimulated 
with increasing concentrations of DAMGO or morphine for 1 h (n=4). Raw BRET ratio of vehicle-
treated cells was subtracted and raw bioluminescence data from β-Gal were normalized to 
vehicle-treated cells.  (G) HEK293 cells expressing MOP-RLuc8 and β-arrestin2-YFP (BRET) were 
incubated in a control or 30 µM Cmpd101 pretreatment condition for 30 min prior stimulation 
with 1µM DAMGO or morphine (n=4). Area under the curve (AUC) is expressed as a percentage of 
the maximal response of DAMGO in the control and is shown as the mean±SEM. ^ denotes 
significance vs control (p<0.01), two-way ANOVA with Dunnett's multiple comparison test. n, 
number of experiments 
Figure 6. GRK recruitment to activated wild-type MOP. (A) HEK293 cells expressing MOP-YFP and 
GRK2-mTurquoise (FRET) were stimulated with 10 µM DAMGO or 30 µM morphine for 1 min prior 
to agonist washout (n=6). (B, C) HEK293 cells expressing MOP-RLuc8 and GRK2-Venus (BRET) were 
stimulated with 1 µM DAMGO or morphine for 20 min prior further addition of 30 µM naloxone 
(B) or for 10 min with increasing concentrations of DAMGO and morphine (C) (both n=3). (D) 
HEK293 cells expressing MOP-β-Gal1-44 and GRK2-β-Gal45-1043 (β-Gal complementation) were 
stimulated with increasing concentrations of DAMGO or morphine for 1 h (n=4). For BRET/FRET, 
data from vehicle-treated cells was subtracted, and for β-Gal the data were normalized to vehicle-
treated cells. Data represent mean±SEM. (E) HEK293 cells expressing MOP-RLuc8 and GRK2-Venus 
(BRET) were incubated with control or 30 µM Cmpd101 for 30 min prior to stimulation with 1 µM 
DAMGO or morphine. The 10 min area under the curve (AUC) was quantified and is expressed as a 
percentage of the maximal response of the control-treated DAMGO response (n=4). Data are 
expressed as mean±SEM. ^ denotes significance vs control (p<0.01) in two-way ANOVA with 
Dunnett's multiple comparison test. n, number of experiments 
Figure 7. GRK2 recruitment to phosphorylation-deficient MOP mutants. (A, B) HEK293 cells were 
transiently transfected with MOP-RLuc8 WT or phosphorylation-deficient mutants and GRK2-
Venus (BRET) and stimulated for 30 min with 1 µM DAMGO (A) or for 10 min with increasing 
concentrations of DAMGO or morphine (B) (both n=3). The BRET ratio of vehicle-treated cells was 
subtracted and data represent mean±SEM. The area under the curve (AUC) is expressed as a 
percentage of the maximal response to DAMGO by the WT receptor and represents mean±SEM. 
All responses are significant vs vehicle; ^ denotes significance vs WT (p<0.01), two-way ANOVA 
with Dunnett's multiple comparison test; * denotes significance of DAMGO vs morphine (p<0.01), 
two-way ANOVA with Sidak's multiple comparison test. (C) HEK293 cells expressing MOP-β-Gal1-
44 WT or phosphorylation-deficient mutants and GRK2-β-Gal45-1043 (β-Gal complementation) 
were stimulated with increasing concentrations of DAMGO for 1 h (n=3-4). Data were normalized 
to vehicle-treated cells, and represent the mean±SEM. (D) HEK293 cells expressing MOP-YFP 
phosphorylation-deficient mutants and GRK2-mTurquoise (FRET) were stimulated with 10 µM 
DAMGO or 30 µM morphine for 1 min prior to agonist washout (left panel n=14 for WT and n=17 
for S375A; right panel n=14 for WT and n=13 for 11S/T-A). n, number of experiments 
Figure 8. Acute desensitization in perforated patch clamp vs whole cell patch clamp recording 
mode by different MOP mutants. Extent of desensitization was determined by exposure to a 
submaximal concentration of ME (M; 10nM, in red), as described in the text, before and after 
exposure to supramaximal concentrations of ME (10µM, orange) as shown in traces A, B and C.  
(A) Exemplar records of MOP-mediated GGIRK for ME-induced desensitization in WT and STANT-3A 
mutant. (B) Exemplar records showing loss of ME induced desensitization only in the STANT-3A 
mutant using whole cell patch clamp and, alternatively (C), in perforated patch clamp mode after 
pre-treatment with 30nM Calphostin-C. (D), (E) and (F) compare acute desensitization using whole 
cell and perforated patch clamp recordings in different mutants (n=5 for each cell type). All scale 
bars represent 0.2 nS and 1 min. Two-way ANOVAs for D), (E) and (F) were all significant for main 
effects. Post hoc comparisons (Bonferroni corrected) were significant where shown (**** P < 
0.0001). In (D) post- compared with pre-desensitized response [100 %]; the main effect of ME vs 
morphine was not significant (P > 0.05).  
	
TABLES 
Table 1. Potency (pEC50) and maximal response (Emax) of b-arrestin1 and 2 recruitment to wild-





Emax   




(% of DAMGO) 
b-arrestin1 DAMGO 6.05 ± 0.06 (0.89) 100 5.82 ± 0.07 (1.51) 100 Morphine - - - - 
b-arrestin2 DAMGO 6.28 ± 0.04 (0.52) 100 5.94 ± 0.03 (1.15) 100 Morphine 6.12 ± 0.05 (0.76) 33.57 ± 2.18 6.00 ± 0.05 (1.00) 39.91 ± 1.01 
 
Table 2. Potency (pEC50) and maximal response (Emax) of β-arrestin1 recruitment to 





 (% of WT DAMGO) 
pEC50 
Emax  
(% of WT DAMGO) 
WT DAMGO 6.05 ± 0.06 100 5.82 ± 0.07 100 Morphine - - - - 
TSST-4A DAMGO 6.10 ± 0.06 91.59 ± 1.56 5.86 ± 0.05 36.33 ± 6.79  
Morphine - - - - 
S375A DAMGO 5.89 ± 0.07  36.20 ± 6.27^ 6.71 ± 0.13 32.20 ± 5.73 Morphine - - - - 
TREHPSTANT-
4A 
DAMGO - - 5.95 ± 0.48  28.47 ± 7.18 
Morphine - -  - - 
11S/T-A DAMGO - - 8.27 ± 1.74 23.46 ± 2.33 Morphine - - - - 
 




Table 3. Potency (pEC50) and maximal response (Emax) of β-arrestin2 recruitment to 





(% of WT DAMGO) pEC50 
Emax  
(% of WT DAMGO) 
WT DAMGO 6.28 ± 0.04 100 5.94 ± 0.03 100 Morphine 6.12 ± 0.05 33.57 ± 2.18 - - 
TSST-4A DAMGO 6.36 ± 0.02 94.08 ± 3.76 5.58 ± 0.05 56.73 ± 7.61 Morphine 5.85 ± 0.14 29.21 ± 4.11   
S375A DAMGO 6.30 ± 0.01 71.73 ± 6.47^ 6.08 ± 0.18 49.36 ± 16.95 Morphine 6.37 ± 0.14 17.31 ± 0.90^ - - 
STANT-3A DAMGO 6.20 ± 0.06 56.26 ± 1.81^ NA NA Morphine 6.40 ± 0.08 14.76 ± 1.66^  NA NA 
TREHPSTANT- 
4A 
DAMGO NA NA 5.72 ± 0.05 42.55 ± 6.31 
Morphine NA NA - - 
11S/T-A DAMGO 6.16 ± 0.02 41.90 ± 5.48^ 6.08 ± 0.17 43.73 ± 5.16 Morphine 6.29 ± 0.08 15.92 ± 1.67^   
 
^ denotes significance vs WT (p<0.01) two-way ANOVA with Dunnett's multiple comparison test. 
Table 4. Potency (pEC50) and maximal response (Emax) of β-arrestin2 recruitment with GRK 





(% of mock DAMGO) pEC50 
Emax 
(% of mock or SRC) 
Mock DAMGO 6.50 ± 0.02 100 5.72 ± 0.02 100 Morphine 5.95 ± 0.05 25.72 ± 2.10 6.51 ± 0.38 100 
GRK2-WT 
      OE 
DAMGO 8.03 ± 0.04^ 176.43 ± 8.43^ 5.81 ± 0.01 128.98 ± 17.03 
Morphine 7.33 ± 0.05^ 146.06 ± 6.18^ 6.16 ± 0.26 183.99 ± 28.26 
GRK2-DN 
      OE 
DAMGO 6.41 ± 0.03 62.23 ± 3.18^ - - 
Morphine 6.55 ± 0.02 12.56 ± 1.66 - - 
GRK3-WT 
      OE 
DAMGO NA NA 6.51 ± 0.03 157.94 ± 18.66 
Morphine NA NA 6.05 ± 0.14 144.58 ± 40.65  
SCR  DAMGO NA NA 5.71 ± 0.13 100 Morphine NA NA - - 
GRK2 KD DAMGO NA NA 6.09 ± 0.12 72.39 ± 4.35 Morphine NA NA - - 
GRK3 KD DAMGO NA NA 6.14 ± 0.15 85.64 ± 2.51 Morphine NA NA - - 
 
^ denotes significance vs WT (p<0.01) two-way ANOVA with Dunnett's multiple comparison test. 
Table 5. Potency (pEC50) and maximal response (Emax) of GRK2 recruitment to wild type MOP by 
BRET and b-Gal complementation.  
MOP WT BRET b-Gal pEC50 Emax   pEC50  Emax 
(EC50 µM) (% of DAMGO) (EC50 µM) (% of DAMGO) 




Table 6. Potency (pEC50) and maximal response (Emax) of GRK2 recruitment to phosphorylation-





(% of WT DAMGO) pEC50 
Emax  
(% of WT DAMGO) 
WT DAMGO 6.22 ± 0.14 100 6.39 ± 0.12 100 Morphine 6.37 ± 0.20 37.88 ± 7.22 - - 
TSST-4A DAMGO 6.50 ± 0.13 99.02 ± 9.38 5.72 ± 0.11 45.35± 1.58^ Morphine 6.47 ± 0.08 42.72 ± 11.93 - - 




DAMGO 5.77 ± 0.15 58.33 ± 6.62^ 6.15 ± 0.38 36.73 ± 4.27^ 
Morphine 5.63 ± 0.51 26.77 ± 5.45 - - 
11S/T-A DAMGO 5.77 ± 0.08 53.33 ± 2.48^ 6.13 ± 1.46 33.86 ± 3.64^ Morphine 5.57 ± 0.05 23.20 ± 3.11 - - 
 
^ denotes significance vs WT (p<0.01) two-way ANOVA with Dunnett's multiple comparison test. 
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